58758-40-0

Basic information

• Product Name: 6-Nitro-2-(p-tolyl)benzo[d]oxazole
• Synonyms: 6-Nitro-2-(p-tolyl)benzo[d]oxazole
• CAS NO: 58758-40-0
• Molecular Formula: C₁₄H₁₀N₂O₃
• Molecular Weight: 254.2408
• Mol File: 58758-40-0.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Nitro-2-(p-tolyl)benzo[d]oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Nitro-2-(p-tolyl)benzo[d]oxazole(58758-40-0)
• EPA Substance Registry System: 6-Nitro-2-(p-tolyl)benzo[d]oxazole(58758-40-0)

Safety Data

• Hazardous Substances Data: 58758-40-0(Hazardous Substances Data)

Upstream product

• 54367-81-6 7-nitro-3-p-tolyl-2⁽⁴⁾H-benzo[1,2,4]oxadiazine 
• 17200-30-5 6-nitrobenzo[d]oxazole 
• 104-87-0 4-methyl-benzaldehyde 
• 98-59-9 p-toluenesulfonyl chloride 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 104-85-8 para-methylbenzonitrile 
• 121-88-0 5-Nitro-2-aminophenol 
• 874-60-2 4-methyl-benzoyl chloride 
• 99-94-5 p-Toluic acid 

Downstream Products

• 69657-63-2 2-p-tolylbenzo[d]oxazol-6-amine 

Relevant articles and documents

Iodine-mediated arylation of benzoxazoles with aldehydes

A simple and efficient methodology for the arylation of benzoxazoles with aldehydes using iodine as the mediator has been developed. The reaction proceeded smoothly with a range of substrates to give the corresponding arylated products in moderate to good yields.

Synthesis of benzoxazoles by the copper triflate catalysed reaction of nitriles and o-aminophenols

An efficient procedure for the synthesis of benzoxazoles by the heteroannulation of nitriles and o-aminophenols in the presence of a catalytic amount of copper(II) trifluoromethanesulfonate, has been developed. This method represents a practical and attractive alternative for the synthesis of both 2-arylbenzoxazoles and 2-alkylbenzoxazoles.

TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.